Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001369965 | SCV001566424 | uncertain significance | not provided | 2023-08-30 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant is likely to be disruptive. ClinVar contains an entry for this variant (Variation ID: 1060524). This variant has not been reported in the literature in individuals affected with VCAN-related conditions. This variant is present in population databases (rs764734647, gnomAD 0.02%). This sequence change replaces valine, which is neutral and non-polar, with phenylalanine, which is neutral and non-polar, at codon 2080 of the VCAN protein (p.Val2080Phe). |
Ambry Genetics | RCV002550094 | SCV003529075 | uncertain significance | Inborn genetic diseases | 2021-10-29 | criteria provided, single submitter | clinical testing | The c.6238G>T (p.V2080F) alteration is located in exon 8 (coding exon 7) of the VCAN gene. This alteration results from a G to T substitution at nucleotide position 6238, causing the valine (V) at amino acid position 2080 to be replaced by a phenylalanine (F). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |